Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• LIM kinases (LIMK1/2) regulate actin cytoskeleton dynamics through cofilin phosphorylation.
• Dysregulation and overexpression of LIMKs are linked to diseases like cancer, Fragile X syndrome, and glaucoma.
• LIM kinases are attractive drug targets due to their position downstream of Rho GTPase signaling.

Purpose of the Study:

• To develop Proteolysis Targeting Chimeras (PROTACs) to disrupt both catalytic and non-catalytic functions of LIM kinases.
• To investigate isoform-specific degradation of LIMK1 and LIMK2 using PROTAC technology.

Main Methods:

• Design and optimization of PROTACs targeting LIMK1/2.
• Cell-based assays to evaluate PROTAC efficacy and specificity.
• Structural analysis to understand the basis of isoform selectivity.

Main Results:

• Initial PROTACs demonstrated isoform-specific LIMK2 degradation, despite targeting both LIMK1/2 with a dual inhibitor warhead.
• Optimization yielded a highly potent and selective LIMK2 degrader.
• Isoform specificity is attributed to favorable orientation bias, lysine accessibility, and enhanced ternary complex formation.

Conclusions:

• A novel chemical probe was developed for isoform-specific LIMK2 degradation.
• This PROTAC offers a powerful alternative to conventional reversible pan-LIMK inhibitors.
• The findings provide a new tool for studying LIMK functions and related diseases.